Cardiac Insight Expands Cardea SOLO™ Wearable ECG Reporting to Include Select Heart Block Detection

Leading ECG analysis platform drives greater clinical impact of Cardea SOLO™ Sensor technology with new arrhythmia detection capabilities

Bellevue, WA (June 12, 2020) — Cardiac Insight, Inc., a healthcare innovator specializing in wearable cardiac sensors and automated electrocardiogram (ECG) analysis software, announces new software advancements for its Cardea SOLO™ Wearable ECG platform. The Cardea SOLO™ system, with its proven arrhythmia diagnosis technology, now includes select heart block detection and advancements in proprietary noise management algorithms for increased reporting precision.

Cardea SOLO™ combines a single-use prescription wearable ECG sensor with in-clinic automated analysis software managed by clinicians – the only solution of its kind. The platform enables hospitals and private practice cardiologists to eliminate costly ECG analysis outsourcing to recapture vital revenues, provide more timely diagnosis, and keep patient data securely in-house.

"Cardiac Insight is accelerating our innovation and deployment pace to meet new and rapidly evolving demands placed on health systems and private practice cardiologists by the response to COVID-19. We’re seeing more and more physicians and healthcare institutions adopting the Cardea SOLO™ platform to increase productivity through lower costs, eliminating outsourcing delays, increasing data security, and providing a telehealth solution,” said Robert Odell, Cardiac Insight President and Chief Operating Officer.

Heart block describes a group of cardiac electrical conduction disorders of varying types and severity. Some types of heart block are congenital while others are associated with increased age over 70 years, and in individuals with structural disorders of the heart such as valvular heart disease. Bradycardia, a heart rate that’s too slow and often associated with Heart Block, accounts for more than 30,000 annual emergency department visits annually in the U.S. alone. A heart block can cause a patient’s cardiac electrical signal to slow down, or even stop, as it travels between the chambers of the heart.

Heart Block can cause lower heart rates and less efficient blood circulation with increased risk of dizziness, loss of consciousness, low blood oxygen, heart failure and even sudden cardiac death if not detected and treated.

The Cardea SOLO Sensor wearable is typically applied to the patient in a hospital clinic or a physician’s office. It can also ship directly from Cardiac Insight or the clinic location to the
patient for self-application through Cardiac Insight’s Cardea SOLO Heart@Home™
telehealth program.

After an optimal seven-day wear period, the patient removes and returns their sensor to
the cardiologist’s office by mail or in person. Cardea SOLO’s robust, algorithm-based ECG
software which detects arrhythmias including atrial fibrillation (AFib), then analyzes the
sensor data in-office, producing a comprehensive report within five minutes to direct
clinical decision-making.

Complete program information and telehealth resources are available on request here.

ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. digital
healthcare innovation company specializing in the development of medical-grade, body-worn sensor
technology and automated cardiac analysis solutions through its proprietary algorithms and software
platforms. The company’s products include the Cardea SOLO™ wearable ECG Sensor and Software Analysis
System, and the Cardea 20/20 ECG™ – the only resting ECG System designed for cardiac risk screening in
young athletes at all levels of play.